среда, 21 декабря 2016 г.

MediciNova Announces European Commission Grants Orphan Medicinal...

MediciNova Announces European Commission Grants Orphan Medicinal...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that the European Commission has granted Orphan Medicinal Product Designation for MN-166 for the treatment of amyotrophic lateral sclerosis . OMPD offers potential benefits including protocol assistance, fee reductions, and 10-year market exclusivity once the medicine is on the market in Europe.



from Biotech News